Grantham Mayo Van Otterloo & Co. LLC Purchases 15,027 Shares of Novo Nordisk A/S $NVO

Grantham Mayo Van Otterloo & Co. LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 24.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 76,612 shares of the company’s stock after purchasing an additional 15,027 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Novo Nordisk A/S were worth $4,251,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Martin Capital Partners LLC lifted its holdings in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after purchasing an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas grew its holdings in Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its holdings in Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after buying an additional 37,453 shares in the last quarter. Markel Group Inc. raised its position in shares of Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $1,294,000. 11.54% of the stock is owned by institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo ends its lawsuit with Hims & Hers and strikes a deal to distribute Wegovy and Ozempic on Hims’ telehealth platform, removing a legal overhang and opening branded digital distribution to Hims’ large customer base — a potential volume and channel expansion catalyst. Reuters: Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic
• Positive Sentiment: Novo confirmed an ongoing share repurchase programme (part of up to DKK 15bn over 12 months) — a direct capital‑allocation action that supports the share price by reducing float and signaling management confidence in cash generation. GlobeNewswire: Share repurchase programme
• Neutral Sentiment: Analyst coverage is mixed — broker consensus remains around a “Hold” and forecasts for FY26 EPS are being debated; that keeps upside expectations tempered even as fundamentals remain strong. American Banking News: Broker consensus “Hold”
• Neutral Sentiment: Industry commentary notes Novo’s strong margins and cash flow versus peers (a structural strength) but frames current moves as part of a “comeback” that still depends on competitive management and product cadence. Seeking Alpha: Novo’s quiet comeback begins
• Negative Sentiment: Analyst notes and media pieces warn Novo has lost significant market value recently amid intensifying competition from rivals (e.g., Lilly) and possible future price cuts across its GLP‑1 franchise — ongoing downside risk to revenue and margins if pricing or market share erodes. Zacks: NVO sheds nearly $50B in market cap
• Negative Sentiment: Recent 13F activity shows some institutional trimming (example: Cresset Asset Management sold shares), which can add selling pressure if part of a broader reallocation trend. DefenseWorld: Institutional selling by Cresset

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NVO shares. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $53.93.

Novo Nordisk A/S Stock Performance

NVO stock opened at $39.77 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The business has a 50-day moving average price of $51.18 and a 200 day moving average price of $52.24. The company has a market capitalization of $177.59 billion, a P/E ratio of 11.46 and a beta of 0.74. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.